Neonatal HIV Early Infant Diagnosis (EID) Versus Standard of Care EID- Long Term Impact on inFant hEalth (LIFE)

NCT ID: NCT04032522

Last Updated: 2024-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

6602 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-23

Study Completion Date

2023-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study we will evaluate the benefit of HIV testing in neonates born from HIV-infected mothers in Tanzania and Mozambique. The study will use and evaluate novel point-of-care diagnostic systems, that can provide neonatal HIV test results within 2 hours. We will evaluate if HIV testing at birth followed by immediate neonatal HIV treatment initiation will lead to lesser infant's sickness, HIV progression or even death as compared to the current standard procedure which is infant HIV testing at week 6 after delivery. This will be associated with a cost-effectiveness analysis in order to guide national HIV programs for their guidelines. The study will further evaluate if point-of care viral load testing in mothers at birth will identify high-risk scenarios for HIV transmission from the mother to her child. This should lead to enhanced prophylactic treatments in HIV-exposed infants and we hypothesize that PoC VL monitoring at birth leads to lower transmission rates. The study will be performed at 28 maternity health facilities in Tanzania and Mozambique, half of them will be randomized to provide birth HIV PoC infant and maternal viral load testing, the other half will provide the current standard of care (infant HIV testing at week 6, no PoC VL monitoring at birth for the mother). The study is conducted in public health settings, and some study objectives also focus on how successful modern HIV treatments can be provided to infants, if HIV testing and treatment procedures are feasible for nurses and midwives, and if these procedures can be carried out in a timely manner. This study also includes a basic research component that will investigate how HIV spreads in the body of HIV-infected infants, and if early infant HIV diagnosis and treatment can reduce the spread in cells of HIV-infected individuals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV, Neonatal HIV Early-Infant-Diagnosis (EID), Point-of-Care Testing (PoC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm (A)

Half of the health facilities will implement the intervention package. All mothers will be tested using PoC-VL at delivery and all HIV-exposed infants will be offered PoC-EID at birth and week 4-8. Newborns found to be HIV-positive will be offered immediate ART. Neonatal ART initiation will be supported at birth by trained nurses/midwives, and approved and supervised by local doctors from the affiliated HIV CTC. Following ART initiation infants will be referred for consolidated ART management to their paediatric HIV clinic following local procedures. Newborns testing HIV-negative will be offered postnatal prophylaxis (PNP) or enhanced postnatal prophylaxis (ePNP), depending on clinical risk factors, the maternal VL and country guidelines. Mothers with HIV-RNA \>1000 copies/mL will receive immediate referral information for ART initiation if not on ART or enhanced ART counselling, with follow up virologic testing and switch of ART regimen as applicable at their local HIV clinic.

point-of care (PoC) neonatal HIV early infant diagnosis (EID)

Intervention Type OTHER

clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)

Control Arm (B)

The other half of the health facilities will implement the standard of care (SoC). Enrolled mothers will not receive immediate PoC VL at delivery, but infants deemed to be at high risk using clinical criteria (e.g. no or late initiation of maternal ART) will be offered ePNP. EID testing will follow the national algorithm with testing at 4-8 weeks, followed by referral for immediate ART initiation for all HIV-infected infants. As PoC EID testing is expected to be nationally implemented on a programme level we will facilitate the availability of PoC testing at these sites.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

point-of care (PoC) neonatal HIV early infant diagnosis (EID)

clinical impact of a PoC-EID for infants and neonates at birth and week 4-8 weeks, linked with nurse-supported immediate ART initiation in HIV-infected neonates, versus standard-of-care (SoC)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Voluntary and informed consent of the mother for her own study participation
2. Voluntary and informed consent of the legal guardian of the child for participation of the child in the study.
3. Mothers/legal guardians ≥18 years of age.
4. Documented maternal HIV infection.
5. Willingness to consent to HIV testing for the child and herself.
6. Willingness to consent to active tracing including home tracing.

Exclusion Criteria

1. Deficiency in the mother, rendering it difficult, if not impossible, for her or her infant to take part in the study or understand the information provided to her. This includes alcoholism, drug dependency as well as psychiatric illnesses, suicidal tendencies or any other inability.
2. Having delivered more than 72h (3 days) ago
3. Prisoners
4. Women presenting with an emergency requiring immediate medical assistance if not resolved at study inclusion
5. Stillbirths
6. Infant requiring emergency care (e.g. immediate or rapid occurring life threatening conditions, resuscitation, prolonged obstetric related intensive care, severe jaundice) or born with severe malformation.
7. If within the discretion of the investigator based on recommendation of the gynaecologist or paediatrician in charge study participation would possibly add not acceptable risk or burden to the mother or infant (e.g. significant congenital malformation, health deficiencies, very low birth weight less than 1500g)
8. Unlikely to comply with protocol as judged by the principal investigator or his designate
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto Nacional de Saúde, Mozambique

OTHER_GOV

Sponsor Role collaborator

NIMR- Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania

UNKNOWN

Sponsor Role collaborator

University of Lisbon Instituto Universitário Egas Moniz (IUEM) Lisbon, Portugal

UNKNOWN

Sponsor Role collaborator

Clinton Health Access Initiative Inc.

OTHER

Sponsor Role collaborator

Michael Hoelscher

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Hoelscher

Director, Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Arne Kroidl, Dr. med

Role: STUDY_CHAIR

Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich

Ilesh Jani, Dr., Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Instituto Nacional de Saúde, Mozambique

Issa Sabi, Dr.

Role: PRINCIPAL_INVESTIGATOR

NIMR- Mbeya Medical Research Centre (MMRC), Mbeya, Tanzania

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centro de Investigacao Operacional da Beira (CIOB)

Beira, Sofala, Mozambique

Site Status

Mbeya Medical Research Centre

Mbeya, , Tanzania

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mozambique Tanzania

References

Explore related publications, articles, or registry entries linked to this study.

Jani IV, Sabi I, Elsbernd K, Meggi B, Mahumane A, Lwilla AF, Pereira K, Boniface S, Edom R, Lequechane J, Chale F, Chiwerengo N, Ntinginya NE, Mudenyanga C, Mueller M, Rauscher M, Hoelscher M, Taveira N, Buck WC, Kroidl A; LIFE Study Consortium. Impact of Point-of-Care Birth Test-and-Treat on Clinical Outcomes Among Infants With HIV: A Cluster-Randomized Trial in Mozambique and Tanzania. Clin Infect Dis. 2025 Jun 4;80(5):1114-1124. doi: 10.1093/cid/ciae530.

Reference Type DERIVED
PMID: 39514367 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LMU-IMPH-LIFE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Healthy Beginning Initiative
NCT01795261 UNKNOWN
POC HIV Testing and Early DTG Use for Infants
NCT05393193 ACTIVE_NOT_RECRUITING PHASE4